Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. (Nasdaq: RLAY) is a clinical-stage biotechnology company pioneering drug discovery through its Dynamo™ platform, which analyzes protein motion to develop precision therapies for oncology and genetic diseases. This page provides real-time access to official company announcements, research breakthroughs, and strategic developments.
Investors and industry professionals will find curated updates including clinical trial progress, regulatory milestones, and partnership announcements. All content is sourced directly from Relay Therapeutics’ communications and verified financial disclosures, ensuring reliability for decision-making.
Key coverage areas include innovations in small molecule therapeutics, updates on the Dynamo platform’s applications, and analyses of Relay’s position within the precision medicine landscape. Content is organized chronologically for easy tracking of the company’s evolution.
Bookmark this page to monitor Relay Therapeutics’ advancements in targeting historically undruggable proteins. For comprehensive insights into RLAY’s scientific and corporate developments, revisit regularly or subscribe to Stock Titan’s update alerts.
Relay Therapeutics (Nasdaq: RLAY) announced promising interim clinical data for RLY-4008, the first therapy targeting FGFR2, showing approximately 80% of patients with FGFR2-altered tumors achieved tumor size reductions. The company reported a net loss of $67.5 million for Q4 2021, with total cash and investments of $958.1 million as of December 31, 2021, expected to fund operations into at least 2025. Relay also presented preclinical data for RLY-2608, an innovative PI3Kα inhibitor, and outlined significant growth in R&D expenses due to increased clinical activities.
Relay Therapeutics (Nasdaq: RLAY) announced plans to release its fourth quarter and full year 2021 financial results on February 24, 2022, after market close. The company specializes in precision medicine, leveraging advanced computational and experimental technologies to enhance drug discovery. Notably, Relay Therapeutics utilizes its Dynamo™ platform to target challenging protein structures, focusing on therapies for oncology and genetic diseases. A teleconference will not be held alongside this press release.
Relay Therapeutics (Nasdaq: RLAY) will participate in two upcoming healthcare conferences. The first is a fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on February 9, 2022, at 9:30 a.m. ET. Following this, Relay will join a panel discussion at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 12:50 p.m. ET. Both events will be webcast live, and viewers can access them via the Investors & Media page on Relay's website. Archived replays will be available for 30 days post-event.
Relay Therapeutics (Nasdaq: RLAY) has commenced a first-in-human trial for RLY-2608, a pan-mutant PI3Kα inhibitor, dosing its first patient with advanced solid tumors harboring PIK3CA mutations. Simultaneously, it has initiated expansion cohorts for RLY-4008, a selective FGFR2 inhibitor, targeting patients with FGFR2-altered cancers. Both trials aim to evaluate the drugs' safety, tolerability, and efficacy, expanding upon promising prior data. With a robust pipeline and strong financial position, the company is well-positioned to advance its clinical programs and address significant unmet medical needs.
Relay Therapeutics (Nasdaq: RLAY) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 9:45 a.m. ET. Interested parties can access the live webcast through the company's website, with an archived replay available for 30 days post-presentation. Relay Therapeutics specializes in precision medicine, utilizing its innovative Dynamo™ platform to advance drug discovery aimed at targeted oncology and genetic diseases.
Relay Therapeutics (Nasdaq: RLAY) presented promising preclinical data for RLY-2608, a novel allosteric PI3Kα inhibitor, at the 2021 San Antonio Breast Cancer Symposium. The data highlighted the compound's ability to synergize with standard therapies like fulvestrant and abemaciclib, leading to significant tumor regression in breast cancer models. RLY-2608 is designed to selectively target PIK3CA mutant tumors while minimizing toxicity. A first-in-human clinical trial is expected to commence in the first half of 2022, pending FDA approval.
Relay Therapeutics, Inc. (Nasdaq: RLAY) reported third quarter 2021 results, highlighting key advancements in clinical trials and financial performance. The company disclosed interim clinical data for RLY-4008, a selective FGFR2 inhibitor, indicating significant potential. Relay raised $402 million through a follow-on public offering, enhancing its financial position. However, the net loss increased to $60.8 million compared to $36.1 million a year earlier. Cash and investments totaled approximately $616.5 million, expected to fund operations at least until 2025.
Relay Therapeutics (Nasdaq: RLAY) has announced that it will report its third quarter 2021 financial results on November 10, 2021, after market closure. No accompanying teleconference will be held. The company specializes in precision medicine and is focused on enhancing drug discovery, particularly in targeted oncology and genetic diseases, using its proprietary Dynamo™ platform that integrates advanced computational and experimental technologies.
Mark Murcko has been appointed as a Strategic Advisor and Board Member at Octant, bringing over 30 years of biotech experience. Previously, he served as CSO at Dewpoint Therapeutics. Murcko will aid Octant in scaling its chemistry platform and drug discovery process. The company focuses on advancing therapeutics by integrating high-throughput biology and computation since its lab opened in 2019. Octant has established several therapeutic programs showing efficacy in pre-clinical models, positioning itself for significant growth.
Relay Therapeutics (Nasdaq: RLAY) announced a public offering of 13,207,547 shares of its common stock at $26.50 per share, expecting gross proceeds of approximately $350 million before expenses. The underwriters have a 30-day option to purchase an additional 1,981,132 shares.
The offering is set to close around October 15, 2021. This funding aims to enhance Relay's drug discovery processes in targeted oncology and genetic diseases through its advanced Dynamo™ platform.
FAQ
What is the current stock price of Relay Therapeutics (RLAY)?
What is the market cap of Relay Therapeutics (RLAY)?
